Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats

Journal of Orthopaedic Research

Volumn 25, Issue 8, 2007, Pages 1070-1077

  Barrett, Jennifer G ^a,c   Sample, Susannah J ^a   McCarthy, Jenna ^a   Kalscheur, Vicki L ^a   Muir, Peter ^a   Prokuski, Laura ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Alendronate; Bone adaptation; Bone fatigue; Microcracking; Stress fracture

Indexed keywords

ALENDRONIC ACID; SODIUM CHLORIDE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE DENSITY; BONE STRENGTH; BONE STRESS; BONE TISSUE; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; STRESS FRACTURE; ULNA FRACTURE;

ADAPTATION, PHYSIOLOGICAL; ALENDRONATE; ANIMALS; BONE DENSITY; BONE REMODELING; FRACTURES, STRESS; MALE; RATS; RATS, SPRAGUE-DAWLEY; ULNA; ULNA FRACTURES;

EID: 34547808082     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20395     Document Type: Article

References (28)

1. Burr DB, Forwood MR, Fyhrie DP, et al. 1997. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12:6-15.
2. Muir P, Johnson KA, Ruaux-Mason CP. 1999. In vivo matrix microdamage in a naturally occurring canine fatigue fracture. Bone 25:571-576.
3. Muir P, McCarthy J, Radtke CL, et al. 2006. Role of endochondral ossification of articular cartilage and functional adaptation of the subchondral plate in the development of fatigue microcracking of joints. Bone 38: 342-349.
4. Reilly GC, Currey JD. 2000. The effects of damage and microcracking on the impact strength of bone. J Biomech 33:337-343.
5. Hsieh Y-F. Silva MJ. 2002. In vivo fatigue loading of the rat ulna induces both bone formation and resorption and leads to time-related changes in bone mechanical properties and density. J Orthop Res 20:764-771.
6. Colopy SA, Benz-Dean J, Barrett JG, et al. 2004. Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic loading. Bone 2004; 35:881-891.
7. Bennell KL, Malcolm SA, Brukner PD, et al. 1998. A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes. Calcif Tissue Int 63:80-85.
8. Lanyon L, Skerry TM. Postmenopausal osteoporosis as a failure of bone's adaptation to functional loading: a hypothesis. J Bone Miner Res 2001; 16:1937-1947.
9. Milgrom C, Finestone A, Novack V, et al. 2004. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone 35:418-424.
10. Mashiba T, Turner CH, Hirano T, et al. 2001. Effects of suppressed bone turnover by bisphosphonates on micro-damage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531.
11. Danova NA, Colopy SA, Radtke CL, et al. 2003. Degradation of bone structural properties by accumulation and coalescence of microcracks. Bone 33:197-205.
12. Bentolila V, Boyce TM, Fyhrie DP, et al. 1998. Intracortical remodeling in adult rat long bones after fatigue loading. Bone 23:275-281.
13. Millett PJ, Allen MJ, Bostrom MPG. 2002. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg [Am] 84A:236-249.
14. Hayami T, Pickarski M, Wesolowski GA, et al. 2004. The role of subchondral bone remodeling in osteoartbritis. Role of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate transaction model. Arthritis Rheum 50:1193-1206.
15. Astrand J, Aspenberg P. 2002. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 3:19-24.
16. Stepensky D, Golomb G, Hoffman A. 2002. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci 91:508-516.
17. Burr DB, Hooser M. 1995. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of micro-damage produced in vivo. Bone 17:431-433.
18. Arlot M, Meunier PJ. Boivin G, et al. 2005. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253.
19. Guy JA, Shea M, Peter CP, et al. 1993. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283-288.
20. Sato M, Grasser W, Endo N, et al. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
21. Masarachia P, Weinbreb M, Balena. R, et al. 1996. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281-290.
22. van Beek E, Lowik C, van der Pluijm G, et al. 1999. The role of geranlygeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14: 722-729.
23. Mosekilde L, Thomsen JS, Mackey MS, et al. 2000. Treatment with risedronate or alendronate prevents hindlimb immobilization-induced loss of bone density and strength in adult female rats. Bone 27:639-645.
24. Mashiba T, Hirano T, Turner CH, et al. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620.
25. Meunier PJ, Boivin G. 1997. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21:373-377.
26. Stewart GW, Brunet ME, Manning MR, et al. 2005. Treatment of stress fractures in athletes with intravenous pamidronate. Clin J Sport Med 15:92-94.
27. Cao Y, Mori S, Mashiba T, et al. 2002. Raloxifene, estrogen, and alendronate affect the process of fracture repair differently in ovariectomized rats. J Bone Miner Res 17: 2237-2246.
28. Weinstein RS, Chen J-R, Powers CC, et al. 2002. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucorticoids. J Clin Invest 109:1041-1048.